We recently published a list of Why These 10 Firms Recorded Double-Digit Gains Last Week. In this article, we are going to ...

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report ...

AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.

Tempus AI (TEM) has seen a significant surge on Wednesday, with its stock climbing 14.62% in just one day. The significant boost in TEM stock ...

We recently published a list of These 10 Firms Topped Wednesday’s Trading. In this article, we are going to take a look at ...

Tempus AI Inc (NASDAQ:TEM) shares closed up 14.5% following the announcement of expanded strategic partnerships with ...

Many of America’s wealthiest business leaders have lost millions — if not billions — of dollars in net worth since the start of the year, as President Donald Trump’s policies hit markets. But some ...

Tempus stands to earn $200 million in data licensing and model development fees from the collaborations, the release said.

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ...